Matthew Allen Cromie
Directeur Technique/Scientifique/R&D chez Eleison Pharmaceuticals, Inc.
Profil
Matthew Allen Cromie is currently working as Vice President-Clinical Research at Eleison Pharmaceuticals, Inc. He previously worked as Associate Director-Clinical Operations at Cornerstone Pharmaceuticals, Inc. and Hengrui Therapeutics, Inc. He also worked as Senior Manager-Clinical Research at Emergent BioSolutions, Inc. Cromie completed his graduate degree from Northwestern University in 2012 and his undergraduate degree from Michigan Technological University in 1989.
Postes actifs de Matthew Allen Cromie
| Sociétés | Poste | Début |
|---|---|---|
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Matthew Allen Cromie
| Sociétés | Poste | Fin |
|---|---|---|
| Hengrui Therapeutics, Inc. | Corporate Officer/Principal | - |
| EMERGENT BIOSOLUTIONS INC. | Directeur Technique/Scientifique/R&D | - |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - |
Formation de Matthew Allen Cromie
| Michigan Technological University | Undergraduate Degree |
| Northwestern University | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Hengrui Therapeutics, Inc. | |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
